BR112018073861A2 - métodos de terapia de genes para doenças e condições relacionadas com a idade - Google Patents

métodos de terapia de genes para doenças e condições relacionadas com a idade

Info

Publication number
BR112018073861A2
BR112018073861A2 BR112018073861-1A BR112018073861A BR112018073861A2 BR 112018073861 A2 BR112018073861 A2 BR 112018073861A2 BR 112018073861 A BR112018073861 A BR 112018073861A BR 112018073861 A2 BR112018073861 A2 BR 112018073861A2
Authority
BR
Brazil
Prior art keywords
conditions
age
related diseases
gene therapy
therapy methods
Prior art date
Application number
BR112018073861-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Davidsohn Noah
M. Church George
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of BR112018073861A2 publication Critical patent/BR112018073861A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
BR112018073861-1A 2016-05-20 2017-05-22 métodos de terapia de genes para doenças e condições relacionadas com a idade BR112018073861A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662339182P 2016-05-20 2016-05-20
US62/339,182 2016-05-20
US201662421665P 2016-11-14 2016-11-14
US62/421,665 2016-11-14
PCT/US2017/033815 WO2017201527A2 (en) 2016-05-20 2017-05-22 Gene therapy methods for age-related diseases and conditions

Publications (1)

Publication Number Publication Date
BR112018073861A2 true BR112018073861A2 (pt) 2019-02-26

Family

ID=60326179

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073861-1A BR112018073861A2 (pt) 2016-05-20 2017-05-22 métodos de terapia de genes para doenças e condições relacionadas com a idade

Country Status (9)

Country Link
US (2) US12281154B2 (https=)
EP (1) EP3458585A4 (https=)
JP (4) JP7632835B2 (https=)
CN (2) CN117535350A (https=)
AU (2) AU2017268469C1 (https=)
BR (1) BR112018073861A2 (https=)
CA (1) CA3025020A1 (https=)
MX (3) MX2018014256A (https=)
WO (1) WO2017201527A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11208443B2 (en) * 2017-02-14 2021-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. NAF-1 derived peptides and uses thereof
CN110546257B (zh) * 2017-03-17 2024-03-01 阿德夫拉姆生物技术股份有限公司 用于增强基因表达的组合物和方法
WO2018215613A1 (en) * 2017-05-24 2018-11-29 Universitat Autonoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
IL306098A (en) 2017-05-24 2023-11-01 Univ Barcelona Autonoma Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21)
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
KR20200077534A (ko) * 2017-10-20 2020-06-30 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 이종 단백질 생성을 위한 인공 분비 펩티드
WO2019113061A1 (en) * 2017-12-06 2019-06-13 Klogene Therapeutics, Inc. Compositions and methods for modulating gene expression
WO2020047472A1 (en) * 2018-08-30 2020-03-05 Research Institute At Nationwide Children's Hospital Gene therapy for the treatment of galactosemia
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
US12134772B2 (en) 2018-11-21 2024-11-05 Advantage Therapeutics, Inc. Increasing gene expression
CN113227126A (zh) * 2018-11-26 2021-08-06 巴塞罗那自治大学 成纤维细胞生长因子21(fgf21)基因治疗
KR20220030945A (ko) 2019-05-23 2022-03-11 크리스티아나 케어 헬스 서비시즈 인코포레이티드 암의 치료를 위한 nrf2의 유전자 녹아웃
WO2020237208A1 (en) 2019-05-23 2020-11-26 Christiana Care Health Services, Inc. Gene knockout of variant nrf2 for treatment of cancer
US20230038502A1 (en) 2019-06-11 2023-02-09 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
US10653731B1 (en) * 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
KR102281858B1 (ko) * 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
WO2021050970A1 (en) * 2019-09-13 2021-03-18 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
EP4048800A1 (en) 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
CN110894508B (zh) * 2019-10-31 2021-08-06 内蒙古大学 一种调控白色脂肪棕色化的基因Adra1a的应用
CA3160033A1 (en) * 2019-12-05 2021-06-10 Paloma Martinez REDONDO Methods for treating osteoarthritis
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
JP2023524010A (ja) * 2020-04-28 2023-06-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 高効率遺伝子送達系
WO2021231730A1 (en) * 2020-05-13 2021-11-18 Lysogene Compositions and methods for treating gm1 gangliosidosis and other disorders
EP4157317A1 (en) * 2020-05-26 2023-04-05 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy for central nervous system disorders
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途
WO2022115739A2 (en) * 2020-11-30 2022-06-02 Cellular Longevity, Inc. Lnp and liposome compositions for longevity in mammals and methods of using the same
US20220186252A1 (en) 2020-12-16 2022-06-16 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
KR102590276B1 (ko) * 2021-01-04 2023-10-16 부산대학교 산학협력단 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113088531B (zh) * 2021-03-25 2023-10-17 四川省药品检验研究院(四川省医疗器械检测中心) 牛源性成分定量分析标准质粒、制备及检测方法及应用
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
JP2022169389A (ja) * 2021-04-27 2022-11-09 国立大学法人北海道大学 イヌＴＧＦ－β受容体ＩＩ
US12564646B2 (en) * 2021-06-16 2026-03-03 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
US20230018934A1 (en) * 2021-07-16 2023-01-19 Genflow Biosciences Srl Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus
EP4408482A4 (en) * 2021-09-29 2025-11-12 Sirt6 Ltd METHOD OF TREATING A DISEASE
CN114921480A (zh) * 2022-06-09 2022-08-19 国科宁波生命与健康产业研究院 一种骨细胞Terc基因敲除小鼠模型的构建方法
US20260102513A1 (en) * 2022-09-21 2026-04-16 Rejuvenate Bio Gene therapy methods for arrhythmogenic cardiomyopathy
WO2024064785A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for familial partial lipodystrophy
WO2024064784A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for treating mitral valve disease
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物
EP4566618A1 (en) * 2023-12-06 2025-06-11 ADvantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
WO2025109173A1 (en) 2023-11-22 2025-05-30 Advantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
WO2026002276A1 (zh) * 2024-06-28 2026-01-02 艾码生物科技(南京)有限公司 靶向tgfb的rna干扰方法、核酸及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
JP2001515360A (ja) 1997-04-18 2001-09-18 バイオジェン，インコーポレイテッド ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US7419829B2 (en) * 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
WO2003059396A1 (en) 2002-01-11 2003-07-24 Sergei Zolotukhin Adiponectin gene therapy
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
WO2006052568A2 (en) * 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
ATE505489T1 (de) * 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US20070292922A1 (en) 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
JP5421109B2 (ja) 2006-09-13 2014-02-19 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 低カルボキシル化／非カルボキシル化オステオカルシンはベータ細胞増殖、インスリン分泌、インスリン感受性、耐糖能を増加させ、体脂肪量を減少させる
EP2171062A1 (en) * 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US8236557B2 (en) * 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
CA3083324A1 (en) * 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
EP2455104B1 (en) * 2010-11-19 2013-07-17 Universitätsklinikum Freiburg Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
TWI614031B (zh) 2011-11-03 2018-02-11 國立陽明大學 防止皮膚老化相關症狀的醫藥組合物及其使用方法
US9422561B2 (en) 2012-01-24 2016-08-23 Bar-Ilan University Treatment of disease by modulation of SIRT6
CN103665166A (zh) * 2012-09-03 2014-03-26 福又达生物科技股份有限公司 犬融合干扰素
WO2014152993A1 (en) * 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Oklahoma Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions
US10227394B2 (en) * 2014-04-08 2019-03-12 University Of Southern California Polypeptide compositions with type VII collagen fibronectin type III-like repeats and treatment methods for wound closure and healing
KR20150135148A (ko) * 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
SMT202100388T1 (it) * 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10882894B2 (en) * 2015-08-11 2021-01-05 Anie Philip Peptidic TGF-beta antagonists

Also Published As

Publication number Publication date
AU2017268469C1 (en) 2025-01-02
MX2025014039A (es) 2026-01-07
EP3458585A2 (en) 2019-03-27
MX2022000085A (es) 2022-02-10
JP2025078652A (ja) 2025-05-20
EP3458585A4 (en) 2019-10-30
JP7315284B2 (ja) 2023-07-26
JP2019519221A (ja) 2019-07-11
JP2022033855A (ja) 2022-03-02
AU2017268469B2 (en) 2024-07-25
CN117535350A (zh) 2024-02-09
CA3025020A1 (en) 2017-11-23
US20190345224A1 (en) 2019-11-14
CN109844124B (zh) 2023-10-03
AU2017268469A1 (en) 2019-01-03
MX2018014256A (es) 2019-08-16
JP2023078338A (ja) 2023-06-06
US20250122267A1 (en) 2025-04-17
WO2017201527A2 (en) 2017-11-23
US12281154B2 (en) 2025-04-22
JP7632835B2 (ja) 2025-02-19
AU2024219991A1 (en) 2024-10-10
WO2017201527A3 (en) 2018-02-08
CN109844124A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
BR112017025045A2 (pt) plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
EA201891317A2 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
DOP2016000237A (es) Terapia genica para la retinitis pigmentaria
BR112018007453A2 (pt) genes modificados de ataxia de friedreich e vetores para a terapia gênica
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
EA201791624A1 (ru) СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК
BR112015024605A2 (pt) sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
BR112018011838A2 (pt) terapia gênica para distúrbios oculares
BR112017011642A2 (pt) composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
WO2016106458A8 (es) Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje
MX2018004063A (es) Secuencias recombinantes de cromosoma b de maíz y sus usos.
EP3551750A4 (en) GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE I
BR112018009657A2 (pt) métodos de tratamento de distrofia muscular
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2018005872A (es) Profarmacos de acido nucleico.
BR112017011513A2 (pt) tratamento de condições oculares usando células progenitoras
EP3493826A4 (en) MULTIVITAMIN FOR ADVANTAGEOUS GENERAL REGULATION BY MICRO-RNA (MIRNA)

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122026000200-6 PROTOCOLO 870260000824 EM 06/01/2026 11:26.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]